GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Debt-to-EBITDA

Assembly Biosciences (FRA:V7B) Debt-to-EBITDA : -0.05 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Assembly Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.05 Mil. Assembly Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.73 Mil. Assembly Biosciences's annualized EBITDA for the quarter that ended in Mar. 2024 was €-39.36 Mil. Assembly Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Assembly Biosciences's Debt-to-EBITDA or its related term are showing as below:

FRA:V7B' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.16   Med: -0.07   Max: -0.04
Current: -0.04

During the past 13 years, the highest Debt-to-EBITDA Ratio of Assembly Biosciences was -0.04. The lowest was -0.16. And the median was -0.07.

FRA:V7B's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs FRA:V7B: -0.04

Assembly Biosciences Debt-to-EBITDA Historical Data

The historical data trend for Assembly Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Debt-to-EBITDA Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.16 -0.07 -0.04 -0.04

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.02 -0.05 -0.05

Competitive Comparison of Assembly Biosciences's Debt-to-EBITDA

For the Biotechnology subindustry, Assembly Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Debt-to-EBITDA falls into.



Assembly Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Assembly Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.119 + 1.029) / -58.868
=-0.04

Assembly Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.053 + 0.728) / -39.364
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Assembly Biosciences  (FRA:V7B) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Assembly Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (FRA:V7B) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines